ImmunoGen Gelecekteki Büyüme

Future kriter kontrolleri 6/6

ImmunoGen kazanç ve gelirin sırasıyla yıllık 45.8% ve 26% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 45.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 32.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

45.8%

Kazanç büyüme oranı

45.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.6%
Gelir büyüme oranı	26.0%
Gelecekteki özkaynak getirisi	32.1%
Analist kapsamı	Good
Son güncelleme	12 Feb 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means

Feb 09

ImmunoGen, Inc.'s (NASDAQ:IMGN) Intrinsic Value Is Potentially 40% Above Its Share Price

Jan 09

There's Reason For Concern Over ImmunoGen, Inc.'s (NASDAQ:IMGN) Massive 95% Price Jump

Dec 22

ImmunoGen (NASDAQ:IMGN) Is Using Debt Safely

Oct 20

Analysts Just Made A Massive Upgrade To Their ImmunoGen, Inc. (NASDAQ:IMGN) Forecasts

Aug 06

Is ImmunoGen, Inc. (NASDAQ:IMGN) Trading At A 48% Discount?

Jul 20

Forecast: Analysts Think ImmunoGen, Inc.'s (NASDAQ:IMGN) Business Prospects Have Improved Drastically

May 03

ImmunoGen, Inc.'s (NASDAQ:IMGN) Low P/S No Reason For Excitement

Apr 18

Is ImmunoGen (NASDAQ:IMGN) In A Good Position To Deliver On Growth Plans?

Feb 25

What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates

Jan 03

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:IMGN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1,026	435	280	341	7
12/31/2025	778	284	350	313	11
12/31/2024	551	110	187	163	12
12/31/2023	377	23	15	19	11
9/30/2023	288	-74	-200	-198	N/A
6/30/2023	190	-180	-266	-265	N/A
3/31/2023	121	-240	-263	-262	N/A
12/31/2022	109	-223	-231	-230	N/A
9/30/2022	96	-201	-217	-215	N/A
6/30/2022	89	-161	-187	-186	N/A
3/31/2022	92	-129	-167	-166	N/A
12/31/2021	70	-139	-171	-169	N/A
9/30/2021	128	-71	-116	-115	N/A
6/30/2021	137	-56	-112	-111	N/A
3/31/2021	135	-49	-97	-95	N/A
12/31/2020	132	-44	-80	-79	N/A
9/30/2020	91	-71	-121	-120	N/A
6/30/2020	86	-70	-125	-124	N/A
3/31/2020	87	-89	-128	-127	N/A
12/31/2019	82	-104	-91	-88	N/A
9/30/2019	51	-151	-101	-97	N/A
6/30/2019	48	-176	-107	-102	N/A
3/31/2019	42	-174	-113	-106	N/A
12/31/2018	53	-169	-172	-166	N/A
9/30/2018	79	-140	-159	-155	N/A
6/30/2018	77	-150	-71	-69	N/A
3/31/2018	107	-117	-11	-9	N/A
12/31/2017	115	-96	7	8	N/A
9/30/2017	90	-117	0	1	N/A
6/30/2017	89	-105	N/A	-93	N/A
3/31/2017	57	-142	N/A	-150	N/A
12/31/2016	49	-157	N/A	-143	N/A
9/30/2016	53	-156	N/A	-141	N/A
6/30/2016	60	-145	N/A	-124	N/A
3/31/2016	65	-129	N/A	-120	N/A
12/31/2015	57	-119	N/A	-86	N/A
9/30/2015	87	-72	N/A	-68	N/A
6/30/2015	86	-61	N/A	-55	N/A
3/31/2015	79	-57	N/A	-46	N/A
12/31/2014	74	-73	N/A	-66	N/A
9/30/2014	56	-82	N/A	-49	N/A
6/30/2014	60	-71	N/A	-54	N/A
3/31/2014	58	-67	N/A	-46	N/A
12/31/2013	76	-31	N/A	-39	N/A
9/30/2013	49	-59	N/A	-63	N/A
6/30/2013	36	-73	N/A	-60	N/A
3/31/2013	35	-73	N/A	-65	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: IMGN önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.3% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: IMGN önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: IMGN önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: IMGN şirketinin gelirinin (yıllık 26% ) US pazarından (yıllık 8.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: IMGN şirketinin gelirinin (yıllık 26% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: IMGN 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 32.1 %)

ImmunoGen Gelecekteki Büyüme

Future kriter kontrolleri 6/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Forecast breakeven date pushed back to 2024

Price target increased by 10% to US$25.39

Forecast breakeven date moved forward to 2023

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

Forecast breakeven date moved forward to 2024

Price target increased by 8.0% to US$19.00

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means

President notifies of intention to sell stock

Insider notifies of intention to sell stock

ImmunoGen, Inc.'s (NASDAQ:IMGN) Intrinsic Value Is Potentially 40% Above Its Share Price

Forecast breakeven date pushed back to 2024

There's Reason For Concern Over ImmunoGen, Inc.'s (NASDAQ:IMGN) Massive 95% Price Jump

Insider notifies of intention to sell stock

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

Insider exercised options and sold US$3.0m worth of stock

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

New major risk - Share price stability

Price target increased by 10% to US$25.39

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

Insider recently sold US$1.5m worth of stock

Forecast breakeven date moved forward to 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

ImmunoGen (NASDAQ:IMGN) Is Using Debt Safely

Insider exercised options and sold US$1.9m worth of stock

Insider recently sold US$1.3m worth of stock

ImmunoGen, Inc. Announces Executive Changes

Insider notifies of intention to sell stock

Analysts Just Made A Massive Upgrade To Their ImmunoGen, Inc. (NASDAQ:IMGN) Forecasts

President recently sold US$17m worth of stock

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

Forecast breakeven date moved forward to 2024

ImmunoGen, Inc. Announces Executive Changes

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 8.0% to US$19.00

Is ImmunoGen, Inc. (NASDAQ:IMGN) Trading At A 48% Discount?

Price target increased by 13% to US$16.20

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

Consensus revenue estimates increase by 80%

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Price target increased by 18% to US$14.10

Forecast: Analysts Think ImmunoGen, Inc.'s (NASDAQ:IMGN) Business Prospects Have Improved Drastically

Forecast to breakeven in 2025

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ImmunoGen, Inc.'s (NASDAQ:IMGN) Low P/S No Reason For Excitement

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.80 loss, revenue downgraded

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.68 loss in FY 2021)

Forecast to breakeven in 2025

Is ImmunoGen (NASDAQ:IMGN) In A Good Position To Deliver On Growth Plans?

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin